Clinical Trial Update: Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study [Phase 3]

View source ↗

Summary

A Phase 3 trial (TRIDENT) evaluating triple therapy for prevention of recurrent intracerebral events has been terminated; cognitive sub-study ongoing as part of…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebral Small Vessel Diseases
• Cognitive Decline
• Dementia Vascular
• Hypertension
• Intracerebral Hemorrhage
• Stroke Hemorrhagic

Snippet

Sponsor: The George Institute | Conditions: Cognitive Decline, Intracerebral Hemorrhage | Phase 3 | Status: TERMINATED